SIEMENS

@ I I@L.! I

i

With e.soft@,the ability to transfer imagesand Yourpreferencesin acquisition, processingand patient data seamlesslyfrom any modalityis at viewing can all be automated,makingwork yourfingertips. It's that simple. fast and easy.It's that powerful. Jointly developedby Siemensand Toshiba, e.soft@is the ultimatenuclearmedicinesystem.

Correction:e.soft is a joint developmentbetween SiemensandToshiba. Visit our web site at www.siemens-esoft.com ‘I

InstantAccess.Anyware.

Siemensmedical Solutionsthathelp Circle Reader Service No. 181 IL. 9JWU-L@H-LD3J The keenest eye in functional imaging1

@@estinatiooDIgItal A remarkable merging of modalities.

Localization of disease has long remained upgrade to existing VG systems, giving you an elusive diagnostic factor —until now. an attractive, cost-effective route to an extra The Millennium VG ordinary new technology Hawkeye not only detects Hawkeye is the the presence of disease, ultimate version of it utilizes Functional GE's Millennium VG IS I Anatomic Mapping to Series. Based on a identify its location. premium all-digital, Never before has there variable-geometry, been such a superb blending of imaging dual-detector nuclear ______function and form. By merging the functional platform already enhanced with break imaging of PET and SPECT with the anatomi through technologies, our three Millennium cal landmarks of CT, Hawkeye provides you VG systems give you total clinical flexibility with powerful diagnostic information. today and tomorrow. Simply put, Hawkeye has MillenniumVG the potential to change the Hawkeye. Form and way you manage patients. function in a single device

What's more, this GE — with a keen eye on exclusive is available as an your future.

GEMedicalSystems Webringgoodthingstolife.

©2000GeneralElectricCompany gernedicalsysterns.corn

Circle Reader Service No.62 @ i•@ s5@ @55@ 55@E' ‘I ‘@,•@@S : @} Upon Suspicion of Pulmonary Malignancy

@4 Neöjèelu @ F(@tf0rth@@r@arat@ü@@fJ@ch@t@u@Jc @j@ct@ü@ .5

TO Noilifl\@IS1VU@ly C 11a i' act e ri z e s SEE Pulmonary MORE@vIasses

NeoTect, a noninvasive nuclear imaging agent, characterizes pulmonary masses as being rich in somatostatin receptors.'2

@ . 1\iany i@a1ignaut5 pulnioiiaiy niasses an(1 S()1T@einfiaIT@n1at o1@ OVeIeX1)1@(@SSSfl1@ttOSt@1tifl 1eceI)toIs ( SSTRs ) Normal @-@J@E(‘Tii . F'üiuse in l@1ti(@iits \V1H) @t1@kflO\Vfl to hUV(I 01 ai•eh igh ly siis@)(‘(@tfoi ii@a1igiianc@@atul have i)t1l11@)fl@1Y1('S100SOI@CT and/ui (Ilest x—i@iy.

The (‘lifliCI1l)(@fl€'fitOfNeoTect as a popti IatioIl-has€@(1si'eiiing I()()1 @ hasnot beenstu(!ie(I. NeoTectis not an @t1Uiiiativeto CTor hioj @sy. Positive @@-;i@l:(‘1'iii @ I t;i1i@@@i@it( Y ( •(Hull I U @(I @ NeoTect., 1ik(@otliei SiThillP(@Pti(!(@S,lfflI\ iI1(1t1(@hVJ)(@I@11SitiVity1'a(tiOl I1l@-O)I()L!@V(@i1i@@iiiii@ttt;t) 01 afl@1phY1@1(ti( teactions. Adequate tI(@1t11l('flt 1)1OViSiO11@, ifl(1U(1iIl@ (h!)inel)h1in(@. ShOUld he @I\@1iI@1l)1(@f@I iI1@fl1('(1kLte t1S(@.

BER@@X GOTYOUR Nycomed @H SOLUTIONS.Amersham and42%women.Themeanagewas59.0years(18-86years). Deathsdidnotoccurduringtheclinicalstudyperiod.AfterTechnetiumTc99mDepreotideInjection, seriousadverseeventswerenotreported. At leastoneadverseeventoccurredin29/647)4.5%)patientsafterTechnetiumTc99mDepreotide Injection.Headachewasthemostcommonlyreportedadverseevent)1%of patients).Table8lists adverseeventsreportedin0.5%ormoreofpatientswhoreceivedTechnetiumTc99mDepreotide Injection. TABLE8 Kit for the Pre@aratiooof TechoetiumJc 09m Depreoti@eIoject@on ADVERSEEVENTSREPORTEDIN 0.5%OFPATIENTSFOLLOWING NeoTect@'‘N-'c@'flNIN CUNICALTRIALS BrI.fSummaryofPrescribingInformation Numberof PatientsExposed 647 DESCRIPTION Numberof PatientswithAt LeastOneAdverseEvent 29)4.5%) NeoTect'@(KitforthePreparationofTechnetiumTc99mDepreotideInjection)is intendedforusein NervousSystem 13)2%) thepreparationofTechnetiumTc99mDepreotide,adiagnosticradiopharmaceuticalto beusedby Headache 7)1.0%) intravenousinjection.Eachvialcontainsasterile,non-pyrogeniclyophilizedmixtureofSOpgof Dizziness 5)0.8%) Depreotide,5mgofsodiumglucoheptonatedihydrate,50 @igofstannouschloridedihydrate(witha GastrointestinalSystem 7)1.0%) minimumstannoustincontentof15pg),100pgedetatedisodiumdihydrate,andsufficientsodium Nausea 4(0.6%) hydroxideor hydrochloricacidforadjustmenttopH7.4priorto lyophilization.Thelyophilized Vascularlextracardiac)Disorder 3)0.5%) powderissealedunderanitrogenatmospherewitharubberclosure.Theproductcontainsno Rushing 3)0.5%) antimicrobialpreservative. Otheradverseeventswhichoccurredin<0.5%of patientsfollowingadministrationof NeoTecC― Whensterile,non-pyrogenicSodiumPertechnetateTc99mInjection,in0.9%SodiumChloride included:arthrosis,backpain,chestpain,diarrhea,fatigue,gaitabnormality,glossitis,hemoptysis, Injection,U.S.P.,isaddedtothevial,aTechnetiumIc 99mcomplexof Depreotideisformed. hypoaesthesia,infection,legcramps,lymphocytosis,malaise,pharyngitis,somnolence,taste INDICATIONSANDUSAGE perversion. NeoTect@isa scintigraphicimagingagentthatidentifiessomatostatinreceptor-bearingpulmonary DOSAGEANDADMINISTRATION massesin patientspresentingwithpulmonarylesionsoncomputedtomographyand/orchestx-ray Forimaging,NeoTect'@isadministeredasaperipheralintravenousinjectionat asingledoseof 15 whohaveknownmalignancyorwhoarehighlysuspectformalignancy. to 20mCicontainingapproximately50pgofTechnetiumTc99mradiolabeledDepreotidepeptide. CONTRAINDICATIONS Patientsshoulddrinkatleastan8oz.glassofwaterbeforedrugadministration. ThecontentsofKitforthePreparationofTechnetiumTc99mDepreotideInjectionareintendedonly Noneknown. for useinthepreparationoflechnetiumTc99mDepreotideInjectionandarenotto beadministered WARNINGS directiytothepatientOnlyonepatientdoseshouldbedrawnfromeachreconstitutedvial.(See None. InstructionsforthePreparationSection.) PRECAUTiONS Thepotentialneedfor doseadjustmenthasnotbeenstudiedin patientswithrenalinsufficiency,or Ou.ral inpediatricorgeriatricpatients,orinpatientsontherapeuticsomatostatinanalogues. Therapywithsomatostatinanaloguescanproduceseverehypoglycemiainpatientswith IMAGING insulinomas.SinceDepreotidebindsto somatostatinreceptors.cautionshouldbeexercisedwhen PlanarandSPECTimagesofthe chestshouldbeobtainedbetween2-4hoursafterNeoTect@@d administeringthisdrugto patientswithinsulinomas. administration.SPECTimagesofthe chestarerequiredfor optimalimageinterpretation. NeoTect'@,asothersmallpeptides,mayinducehypersensitivityreactionsoranaphylactic RADIATIONDOSIMETRY reactions.Adequatetreatmentprovisions,includingepinephnne,shouldbeavailablefor immediate Basedonhumandata.theabsorbedradiationdoseto anaveragehumanadult)70kg)froman use.Inpreliminarystudiesof 18subjects,NeoTect―@didnotproduceincreasesin lgGor gM production3weeksfollowinginjection.Otherimmuneparameterssuchaseosinophils,other intravenousinjectionoftheagentarelistedinTable9.Thevaluesarelistedindescendingorderas immunoglobulins,complement.lymphokinesorcytokineswerenotstudied. rat/mCiandmGy/MBqandassumeurinarybladderemptyingat4.8hours. TechnetiumIc 99mDepreotideInjection.likeotherradioactivedrugs,mustbehandledwith Table9 EstimatedAbsorbedRadiationDose careandappropriatesafetymeasuresshouldbeusedto minimizeradiationexposureto clinical TargetOrgan red/mCi mGy/MBq personnel.Careshouldalsobetakento minimizeradiationexposuretothepatientconsistentwith Kidneys 0.33 0.090 properpatientmanagement Spleen 0.16 0.042 Radiopharmaceuticalsshouldbeusedbyor underthecontrolof physicianswhoarequalified Testes 0.11 0.031 byspecifictrainingandexperienceinthesafeuseandhandlingofradionuclides,andwhose ThyroidGland 0.088 0.024 experienceandtraininghavebeenapprovedbytheappropriategovernmentalagencyauthorized RedMarrow 0.078 0.021 to licensetheuseof radionuclides. Liver 0.078 0.021 urinaryexcretionof radioactivityoccursprimarilyduringthefirst4 hoursfollowinginjection. Heartwall 0.054 0.014 Studieshavenotbeendoneto determinetheamountofradioactivitythatmightbeeliminatedinthe Bonesurface 0.054 0.015 feces,(SeeClinicalPharmacologySection.lSpecialprecautionsshouldbetakenwithincontinent Lungs 0.053 0.014 patientstominimizetheriskofradioactivecontaminationofclothing,bedlinen,andthepatient's Adrenalglands 0.044 0.012 environment Pancreas 0.037 0.010 lafotastios ForPati•ats Urinarybladder 0.033 0.0089 Tominimizeradiationabsorbeddosetothebladder,adequatehydrationshouldbeencouragedto Uterus 0.031 0.0084 permitfrequentvoidingduringthefirstfew hoursafterinjectionof Neolect―.Thismaybeachieved SmallIntestine 0.019 0.0050 byhavingpatientsdrinkatleastan8oc.glassofwater priorto drugadministration.Tohelpprotect UpperLargeIntestine 0.019 0.0050 themselvesandothersintheirenvironment.patientsshouldtakethefollowingprecautionsfor 12 Ovaries 0.016 0.0042 hoursafterinjection:wheneverpossibleatoiletshouldbeusedandshouldbeflushedseveraltimes LowerLargeIntestine 0.014 0.0038 aftereachuseendpatientsshouldwashtheirhandsthoroughlyaftereachvoidingorfecal DosecalculationswereperformedusingthestandardMIRDmethod(MIRDPamphletNo.1rev., elimination.If blood,urineorfecessoiltheclothing,theclothingshouldbewashedseparately. Soc.NucI.Med..1976).Effectivedoseequivalentwascalculatedinaccordancewith ICRP53 I.aborateiyTests (Ann.ICRP18,1-4,1988)andgaveavalueof0.023mSv/MBq(0.084rem/mCi). Therewasalowincidence(1%orless)oftransientandclinicallyinsignificantchangesin alanine aminotransferase(ALT),whitebloodcellcount.andeosinophilcountfollowingadministrationof 110WSUPPUED TechnetiumTc99mDepreotideInjection. Eachkitis comprisedofonevialcontainingasterile,non-pyrogenic,freeze-driedmixtureof Dniglatsractlea Depreotide,stannouschloridedihydrate,sodiumglucoheptonatedihydrateandedetatedisodium Druginteractionswerenotnotedin clinicalstudiesinwhichTechnetiumTc99mDepreotide dihydrate.Kitsareavailableasindividualvialsoraspacksoffive. Injectionwasadministeredto patientsreceivingconcomitantmedication. NOC64510-511-10-singlevial Carcia.,.essis. Mtitagse.sis.l.pairm.M of Fertility NDC64570-511-05-fivevialpack Studieshavenotbeenconductedto evaluatecarcinogenicpotentialoreffectsonfertility. STORAGE Theresultsofthe followinggenotoxicitystudieswithdecayedTechnetiumTc99mDepreotide Storethekitat -10.C( 14 F).Storethereconstitutedinjectionsolutionat20-2FC)68-77F) Injectionorwithdepreotidewerenegative:Salmonella/Escherichiacolireversemutationassay, usingappropriateradiationshielding.Usewithin5hoursofreconstitution. in vitromouselymphomaassaywithandwithoutmetabolicactivation,andin vivomouse Thekitshouldbeprotectedfromlight micronucleusassay. RxOnly Pregeascy DISIribUtedby PregnancyCategoryC.Animalreproductionstudieshavenotbeenconductedwithdecayed Diatide,Inc. TechnetiumTc99mDepreotideInjection.ft is notknownwhetherTechnetiumTc99mDepreotide 9DeltaDrive Injectioncancausefetalharmwhenadministeredto apregnantwomanorcanaffectreproductive Londonderry,NewHampshire03053 capacity.TechnetiumTc99mDepreotideInjectionshouldbegiventoapregnantwomanonlyif RevisedAugust1999 clearlyneeded.Studiesin pregnantwomenhavenotbeenconducted. NersiegMet@sn References:1.NeoTect@'PrescribingInformation.2.BlumJE,HandmakerH,RinneNA. Studieshavenotbeenconductedwithdepreotideto determineitsexcretioninhumanmilk. Theutilityofasomatostatin-typereceptorbindingpeptideradiopharmaceutical(P829) TechnetiumTc99mPertechnetsteisexcretedinhumanmilk.It isnotknownwhetherTechnetium intheevaluationofsolitarypulmonarynodules.Chest1999115:fl4-232. Tc99mDepreotideInjectionis excretedinhumanmilk.Cautionshouldbeexercisedwhen TechnetiumTc99mDepreotideInjectionis administeredto anursingwoman.Whereverpossible, Neolecf'isatrademarkofDiatide,Inc. infantformulashouldbesubstitutedfor breastmilkuntilthetechnetiumhasbeaneliminated. P.d@ Use Safetyandeffectivenessof Depreotidein pediatricpatientsbelowtheageof 16yearshavenot beenestablished. ADVERSEREACTIONS Adverseeventswereevaluatedin clinicalstudiesof647adultswhoreceived15.0to 20.0mCi TechnetiumTc99mlabeledto approximately50pgof depreotide.Oftheseadults,58%weremen EXPANDINGYOURVISION

BERL@@X CircleReaderServiceNo.9 GOT @M Circle Reader Service No. 135 @8.Amersham 40-4300000708A S

@ See your way clear

Decisiveinformationkeeps you on course

Guidingyouto optimalintervention for neuroendocrinetumors

. Somatostatin receptor scintigraphy with OctreoScan detects and localizes primary tumors and metastatic spread often missed by conventional imaging (sensitivity varies 61%-100%, depending on tumor type).

. Whole-body scanning can more definitively confirm the extent of disease. I.@ •Youare better able to

- stage the patient

- determine diagnostic work-up

- avoid unnecessary procedures

- select optimal treatment

- assess surgical candidates - evaluate response to treatment ILII L Transient adverse effects including dizziness, fever, flush, headache, hypotension, changi@s in liver enzymes, joint pain, nausri, switin@, and weaknesswere observd in h@ hin I @ of 538 patients during Iini ii riik. The ac'c'c@tecIst@nclard @ Pleasesee the @F(@L,(r@nI1t@IIi0)rnit II Il II)I 5@II ( Id @ considerations r (1II1L@pit I( rit@r (IV!n@U 1i for GEP' tumors parentvl(l I flUIhi I()fl I)@( ()fl( urI(rlt I)(tr (It (i(@ ace1@lt(tIl(I11)\' 111(IF)11I(11l@\\‘Ilhl@5@IIiI1@I1@Ior InhI)(ur((Ir(n(lIlLIn(lIun. An emerging choice for sn@aIIcell lungcancer

@ ( ,, Ii ii i i( ) / ),II )( 11@,I/I' 11' @1/t( )(1UI()( I II ii It iii Vii@. V 0 OCTREOSCAN® KitforthePreparationofIndiumIn-i11Pentetreotide

@ j)/( b( @.()()(1(//(1(( (it f)!,@t 1@)t•J)tI( 1 @Liflh!fl.1f@t@!f)r( ‘@(tiI)iI?LlflI()f!1J@lI)fl. for48hoursAmpleifuidt@Makeisnecessaryduringthisperiodasasupportbothtorensieliminationandthe bowel-cleansingprocess.Inapatientwithaninsulinoma,bowel-deansingshouldbeundertakenonlyafter consultationsethanendocrinologist. @;OcmaoSc@® Therecommendedintravenousdoseforg@naiforagingis 111MBq(3.0mO)ofindiumIn-i11pentetreotide preparedfromanOctreoScankit.Therecommendedintravenousdosefor5@E@Iimagingis222MBq(6.0mCi) @ KitforthePreparationofIndiumIn-I PentetreotideofindiumIn-ill pentetreotide. Thedoseshoutsbeconfirmedbyasuitablycalibratedradioactivityiontzationchamberimmediatelybefore administration. BRIEFSUMMARYOF AswithelIintravenouslyadministeredproducts,OctreoScanshouidbeinspectedvisuallyforparticulatematter anddiscolorationpriortoadministration,wheneversolutionandcontainerpermil Preparationscontaining PRESCRIBINGINFORMATiON particulatematterordiscolorationshoutsnotbeadministered.Theyshouldbedisposedofinasafemanner,in compliancewithapplicableregulations. Aseptictechnk@uesandeffectiveshieldingshouldbeemployedinwithdrawingdosesforadministrationtopatients@ DESCRH5TION Waterproo(@ovesshouldbewornduringtheadministrationprocedure. OctreoScan'isa k8forthepreparationol kdiin ln.111pensatreollde,adiagnosticrac8o. DonotadministerOctreoScaninTPNsolutionsorthroughthesameintrawnousline. [email protected] @aaNIconsis8ngof Iwo @onDo&mwiry Theestimatedradiationdoses'totheaverageadult(70kg)fromintravenousadministrationof 111MBq(3mCi) @ 1) A 1O.ml.OctreoScanReaction which arid222MBq(6mCi)arepresentedbelow.TheseestimateswerecalculatedbyOakRidgeAssociated conIwnsa @cphilizedmixtureof 10pg Universitiesusingthedata @shedbyKrenning,ci at' @de. 2) A1O@mLvi&ofIndiumIn-i11GhloddeSlerile EstimatedAbsorbedRadiatiOnDosesafter IntravenousAdministration s@. ofIndiumIn@111Pentetrootide'toa70kgpatient Indiumln.11I pentelreolideispreparedby combirdngIhetwokitcomponents. PLANARSPECT54.16

INDICATiONSANDUSAGE @ ktdiumln@111pentetreolideti anagenttsr8wacinhgraphiclecalizationofprimaryandmetastalicneuroendocrine 5.42 10832 10.83 himorsbeadngsomaloetailnrecepto@ @ 12.15 1.22 2.43 @ C0NTRMND@ONS Spleen 73.86 7.39 147.73 14.77 @ Nonets@cren. Uterus --_ 6.34 063 12.67 1.27 @ WAI*#NGS t@@4,89 0.49 @9.79 0@98 @ DONOTADMINISTERINTOTALPARENTERALNUTR@ON(TPN)ADMIXTURESORIWECTINTOTPN Testes 2.90 Q@2@ I Q5@ INTRAVENOUSADMINiSTRATIONuNES;INThESESOLUT1ONS,ACOMPlEXGLYCOSYLOCTREOT1DE @ CONJUGATEMAYFORM. RedMarrow 3.46 0.35 6.91 1 o.@g @ @j-nflary@- 1@ Thesensitivityofecintigr*tywith @diumln.111pentetreotidemayberedocedmpatientsconcurrentlyreceiving @ ther@ic doMeofoctreotideacetate.Conaideralionshouldbegiventotemporarilysuspendingoctreoilde BladderWail L 30.42 3.04 60.48 6.05 acetatether@ybeforetheadministratIonofindiumIn-i11pentetreohdeandtomonilonngthepatientbr anysigns @ ofwithdrawaL GlTract -@ @ !@c@c:hWa.!_ @_ @7 0.57 11.34 1.13 PRECMJTJCNS @ SmallIntestine 4.78 j 0.48 9.56 0.96 1.Therapywithoctreolideacetalecanproduceseverehypoglycemiainpatientswithinsuhnornas.Since UpperLarge @ pentetreolideleananalogofoctreotkie,anintravenouslineinrecommendedinanypahentsuspectedofhaving @ifl_t@Iw@@ 5.80 0.58 11.59 1.16 aninsulinoma.Anintravenoussolutioncontainingglucoseshouldbeadministeredjustbebreanddunng administrationofindiumln@111pentetreotide. LowerLarge 2.ThecontentsofthetwovialssuppliedwiththekitareintendedonlyforuseinthepreparationofindiumIn-i11 Intestine 7.73 0.77 15.46 1.55 pentetreotideandareNOTtobeadministeredseparatelytothepatient. Adrenals 7.55 0.76 15.11 1.51 3.Sinceindiumln.111pentetreotideiceliminatedprimarilybyrenetaccretion,useinpatientswithvnpairedrenet Thyroid 7.43 0.74 14.86 1.49 @ h@nctIonahotildbe considered. @Effective - 4.Tohe@reducetheradiationdoeetotheIbyroid,kidneys,bladder,andothertargetorgans,patientsshouldbe eel hydratedbabe theadministrationofindiumIn-i11penletreotide.Theyshouldincreasefluidintakeandvoid frequentlyorcr* dayafteractiiilnistrabtxtofthisdrug.Inaddition,IIeirecommendedthatpatientsbe @venamild Dose' @ laxative(e.g.,biaacodhl leotuloee)beinreandaftera&thnistrationoltidumIn-li 1penletreotide(seeDosage Equivalenti3.031.3026.062.61 andActinñstrabonsection). 5.IndkimIn@111pentetreotideshouldbetestedforlabelingyieldofradioactivitypnortoadministration.The prockictmustbeusedwithinsixhoursofpreparation. 1.Values listed includea correctionfora maximumof 0.1% indIumIn-ii4m radiocontaminantat calibration. 8.Componentsofthekitarestedleandnonpyrogenic.TomaintainSIerthty.8isessentietthatctirectionsare 2.ER Krenning,W.H.Baldter,RPM.Kool@,WAP.Breeman,HY.Oa,M.tieJong,J.C.Reubi,T.J.Vases,C. bliowedcarefully.AseptictechniquemustbeusedduringthepreparationandadminietratiOnofindiumIn-li 1 Bruns.D.J.Kwekkeboom,[email protected],J.W.Koper,andS.W.J.Lamberts@SomatostatinReceptor ScintigraphywithIndium-iii.DTPA-D.Phe-i-OctreotideinMan:Metabolism,DosimetryandComparisonwith 7.Octreoilde @tateandthenaturalsomatoetetinhormonem@'beassociatedwithcholelithiasis,presumablyby iodine-i23.Tyr-3.Octreotide@TheJournalofNuclearMedicine,‘@.33,No.5,May1992,pp.652-658. etteringtatetseorpilonandpossiblybydecreasingmotihtyofthegalbadder.AtingledoseofinthumIn-ill 3.Assumes4.8hourvoidingintervalandInternationalCommissiononRadiologicalProtection(ICRP)30modelfor pentetreotideIsnotexpectedtocausecholelithiasis. thegastrointestinaltractcalculations. 8.AswithanyotherradioactivemateriaLappropnatesttielotngshouldbeusedtoavoidunnecessaryradiation 4.EstimatedaccordingtoICRPPublication53. aiposuretothepatient,occupationalworkers,andotherperson& 9.Radiopharmaceutlcalsshoutsbeusedonlybyphysicianswhoarequalifiedbyspecifictreeinginthesafeuse andhardingol radionuclidee. HONSUPPUED TheOctreoScankit NDC0019-9050-40,issuppliedwiththefollowingcomponents: CarctiIOgSnesILMIdagInesILleigirmII*olFertMy 1. A iO.mL @r@5@nReactionVialwhichcontainsalyopliitizedmixtureof: Studieshavenotbeenperlormedwithindiumks-Ill pentetreotidetoeveluatecarcinogenicpolenlbeoreffectson (I) 10pgpentetreotide(N-(diethylenetriamine-N,N,N',N@-tehaacedcacid-N'-acetyf)-D lertilily.Pantetreotidewasevaluatedtsrmutagenicpotentielinaninvitromouselymphomakwwardmutation assayandaninvivomousemicronucleusassay;evidenceofmutagenicitywasnotfound. threoninolcyclic(24) disuffidel,(alsoknownasoctreotideDTPA), (I) 2.0toggentisicacid(2,5-dihydroxybeozoicacid], PregnancyCilegoryC (iii)4.9togtnsodiumcitrate,anbydrous, Antm&reproductionstudieshavenotbeenconductedwithindiumIn-i11pentetreotide.ftsinotknownwhether (iv)0.37togcitricacid.anbydrous,and indiumIn-li 1pentetreotidecancausefetalharmwhenadministeredtoapregnantwomanorcanaffect (v)10.0mginoeltol reproductioncepactly.Therefore,indiumIn-iii pentetreotideshot@dnotbeadministeredtoapregnantwoman Beforetyophilization,sodiumhydroxideorhydrOchiOriCacidmayhavebeenaddedforpHad]ustmenl,Thevial tislesathepotentialbenefitjustifiesthepotentialrisktothefetus. contentsaresterileandnonpyrogenic.Nobacteriostaticpreservativeispresent. 2.A iO-mLvialofIndiumIn-ill ChlorideSterileSolution,whichcontainsil mLof 111MBqOmL(3.0mCiIrnL) indiumIn-i11chloridein0.02NHOattimeofcalthration.Thevialalsoconteinstacit chlorideataconcentration Itsinotknownwhetherthisdrugisexcretedinhumanmilk Becausemanydrugsareexcretedinhumanmiil@ of3.5pglmL(ferricion,12 pglmL).Thevialcontentsaresterileandnonpyrogenic.Nobactehostaticpreservative cautionshoutsbeexercisedwhenindiumIn-i11pentelreotidesiadmiritsleredtoanursingwoman. ispresent. Inaddition,thekitalsocontainsthefollowingitems:(1)a25GaW8@needle(B-D,Monoject)usedtotransfer Psdi@rieUse Indiumtn-i11ChlorideSterileSolutiontotheOctreoScanReactionVoL(2)apressuresensitivelabeLand(3)a Safetyandeffectivenessinchildrenhavenotbeenestablished. packageinsert.

AL@fERSEREACTIONS TheUowingadverseeffectswereobservedindiniceltrialsatafrequencyoflessthan1%of538patients: dizziness,fever,flush,headache,hypotension,changesinliverenzymes,jointpain,nausea.sweating,and weakness.TheseadverseeffectsweretransientAlsoinchiscsitrbes,therewasonereportedcaseof j@DT bradycardlaandonecase01decreasedhemafocrilandhemo@obin. Pentetreothdeisder@ fromoctreotidewhichisusedasatherepeuticagenttocontrolsymptomsfromcertain tumors.TheusueldoseforindiumIn-i11pentetreotideisapprodmately5to20timeslessthanforoctreotideand MalllnckrodtInc., isaubtherapeutlc.Thefollowingadversereactionshewbeenaaaocialedwithoctreotidein3%toiO%ofpatients MallinckrodtNuclearMedicineDMsion nausea,injectionellapain,diarrhea,shdominalpainlctiscombrLloosestools,andvomiting.Hypertensionand P.O.Box5840 leper. @ri4byp@cemiahavealsobeenrepofledwiththeuseofoctreotide. St.Louis,MO 63134

DOSAGEANDADMINISTRATiON i .TermaniniB,GibrilF,ReynoldsIC.ofal.Valueof SomatostatinReceptorScintigraphy:A ProspectiveStudy BeforeadmInistration,apatientshouldbewelhydrated.Afteradministration.thepatientmustbeencouragedto in Gastrinornaof itsEffectonClinicalManagement.Gastroentero!ogr1997;l12:335-337. drinkfluids @er@Eliminationolextrafluiditlakewil he@reducetheradiationdosebyftushtiigoutunbound, @eIIedpenletreotideby @omerularfiltration.Itisalsorecommendedthatamildlaxative(e.g.,bisacod@lor lectulose)begiventothepatientstartingtheeveningbeforetheradioactivedrugisadministered,andcontinuing 01997MallinckrodtInc. M122701 12/97 CircleReaderServiceNo.110 @ IN[4iIEILt@I L'1@ L R

M “@f,@./@ hepatkIncreaseclearing,patient throughput—withhighly.fficientMYOVIEWrapid T@hnethmT@9rnTetrofosminForInjection Giveyournucleardepartment“rapidclearance―capabilfty'withMYOVIEW.MYOVIEW clears quickly from the blood, livefl and Iungs'3for qualily target-to-backgroundratios and timely imaging (as soon as 15 minutesor up to 4 hourspost-injection).1The clearance properties of MYOVIEW allow for highly flexible camera scheduling and enhanced patient management. Any way you look at it, you're cleared for efficiency with MYOVIEW.

In studying patients with known or suspected coronary artery disease, care should be taken to ensure continuouscardiacmonitoringand theavailabilityof emergencycardiactreatment. Please see BriefSummary of Prescribing Informationon adjacent page. ©1998NycomedAmersham References:1.SridharaBS,BractS,RigoP.ci a). Comparisonof myocardia)perfusionimagingwith technetium'99mtetrolosminversusthaIIium@2Olin coronaryarterydisease.AmJ Cardiol. 1993;72(14):10151019. 2. Higley B, Smith FW, Smith 1, et ci. Technettum'99m.l,2-bis[bis(2'ethoxyethy))phosphino]ethane: human biodistribution, dosimetry and safety ofa new myocardia) perfusion imagingagent.J NuciMed. 1993;34(1:30-38. 3. KeIIyJD,ForsterAM, HigleyB, ci ci. Technetiurrr99rrrtetrofosminas a new radiopharmaceutica)for myocardialperfusionimaging.J Nuci Med. 1993;34(2):222-227. MYOVIEW.The image of efficiency. WE'VE ed soumoNs.Amers am MYOVIEW@' MYOVIEW'TM BS-43-1O11A PediatricUse KitforthePreparationofTchnetlumTc99mletrofosmlnforInjection Safetyand effectivenessin pediatricpatientshave not been established. Diagnostic Rediopharmaceutlcal for Intravenous use only ADVERSEREACTIONS Adverseeventswere evaluatedin clinical trials of 764 adults (511 men and 253 women)with RxONLY a meanage of 58.7 years (range29-94 years).The subjectsreceiveda mean dose of 7.67 mCI Please consult full prescrIbIng information before usIng. A summary on the first injectionand 22.4 mCi on the second injectionof Myoview@. Deathsdid not occur during the clinical study periodof 2 days.Six cardiacdeathsoccurred 3 follows: days to 6 months after injection and were thought to be related to the underlying disease or cardiac surgery.After Myoviewinjection,serious episodesof anginaoccurred in 3 patients. DESCRIPTION Overall cardiac adverse events occurred in 5/764 (less than 1%) of patients after Myoview The Macti-PhysicsMyoview kit is supplied as a pack of five vials for use in the preparation injection. ofa technetiumTc99mtetrofoaminintravenousinjectiontobeusedforthescintigraphic The followingeventswere noted in less than 1% of patients: delineation of regions of reversible myocardial ischemia in the presence or absence of Cardiovascular:angina, hypertension,Torsadesde Pointes infarcted myocardlum. Each vial contains a predispensed, sterile, non-pyrogenic, Gastrointestinal:vomiting,abdominaldiscomfort lyophilized mixture of 0.23 mg tetrofosmin (6,9.bis(2-ethoxyethyl)-3,1 2-dloxa-6,9- Hypersensitivity:cutaneousallergy,hypotension,dyapnea diphosphatetradecane]. 30 pg stannous chloride dihydrate (minimum stannous tin 5.0 pg; SpecialSenses:metallictaste, burningof the mouth,smellingsomething maximum total stannous and stannic tin 15.8 pg), 032 mg disodium sulphosalicylate and There was a low incidence (less than 4%) of a transient and clinically insignificant rise in 1.0 mg sodium D-gluconate, and I .8 mg sodium hydrogen carbonate. The lyophilized white bloodcell counts followingadministrationof the agent powder Is sealed under a nitrogen atmosphere with a rubber closure. The product contains no antimicrobial preservative. DOSAGEANDADMINISTRATION CUNICALPHARMACOLOGY Forexerciseand rest imaging,Myoviewis administeredin two doses: The first dose of 5-8 mCi (185-296MBq) is given at peak exercise. General The seconddose of 15-24mCi (555-888MBq) is givenapproximately4 hours later,at rest When technetiumTc99m pertechnetateIs added to tetrofosminin the presenceof stannous reductant,a Ilpophilic,catlonic technetiumTc99m complex rsformed,Tc99m tetrofosmin.This Imagingmay begin 15 minutesfollowingadministrationof the agent complexis the active ingredientin the reconstftuteddrug product,on whose biodistribulionand Dose adjustment has not been establishedin renaily or liver impaired, pediatric or geriatric pharmacokineticpropertiesthe Indicationsfor use depend. patients ClInIcalThals RADIATIONDOSIMETRY A total of 252 patients wfth ischemlc heart disease or atypical chest pain who had a reason fromintravenousBasedon humandata, the absorbedradiationdosesto an averagehumanadult (70 kg) for exercisestress imagingwere studied in two open-label,multi@center,clinicaltrials of Tc99m thefollowing injections of the agent under exercise and resting conditions are listed in tetrofosmin (study a and study b). Of these 252 patients there were 212 (83%) males and 40 assumeurinarytable.The valuesare listedin descendingorderas radlrnCiand pGy/MBqand (17%) females with a mean age of 60.5 years (range 33.7 to 82.4 years). At peak exercise, hours.EstImatedbladderemptyingat 3.5 maximumheart rateachievedand peak SystOliCbloodpressurewerecomparableafter Myoview Absorbed Radiation Dose (T.chn.tlumTcSOmT.trofosmlnInjection)Absorbed and thalllum.201 exerctaestudtas All patients had exercise and rest planar imaging with Myoview and thalllum-201 ; 191 (76%) doseExercise radioston patientsalso had SPECTImaging.The Myoviewand thailium-201imageswere separatedby a RestTarget meanof5.1days(1.14daysbeforeor2-14daysafterMyoview).ForMyoviewImaging,each pGylMBqGallorgan radlmCl pGylMBq radlmCl patient received185.296MBq (5.8 mCi)Tc99m tetrobsmln at peak exercrseand 555.888 MBq (15-24 mCi) Tc99m tetrofosmin at rest approximately4 hours later. For thallium-201 imaging, 48.6Upperbladderwall 0.123 33,2 0.180 patients [email protected] MBq (1.5-2.0mCi) at peak exercise. 30.4Bladderlarge intestine 0.075 20.1 0.113 The images were evaluated for the quality of the image (excellent, good or poor) and the 19.3Lowerwall 0.058 15.6 0.071 diagnosis (with scores of 0 = normal, 1 = ischemia, 2 = infarct, 3 = mixed infarct and 22.2Smalllarge intestine 0.057 15.3 0.082 ischemla).Theprimaryoutcomevariablewasthepercentageof correctdiagnosesin 17.0Kidneyintestine 0.045 12.1 0.063 comparison to the final clinical diagnosis.All planar imageswere blindly read;SPECT images 12.5Salivary 0.039 10.4 0.046 were evaluated by the unblinded Investigator. A subset of 181/252 (71%) patients had 11.6Ovariesglands 0.030 8.04 0.043 coronary anglographycomparisons to the planar images of Myoviewor thallium-201. 9.55Uterus 0.029 7.88 0.035 8.36Bone 0.027 7.34 0.031 INDICATIONSANDUSAGE 5.58Pancreassurface 0.023 6.23 0.021 Myoview is Indicated for scintigraphic imaging of the myocardium following separate 4.98Stomach 0.019 5.00 0.018 adrnlnlatrstlonsunderexerciseand restingconditions.It Is usefulin the delineationof regionsof 4.63Thyroid 0.017 4.60 0.017 reversiblemyocardlalischemiaIn the presenceor absenceof infarctedmyocardium. 5.83Adrenals 0.016 4.34 0.022 4.11Heartwall 0.016 4.32 0.015 CONTRAINDICATIONS 3.93Redmarrow 0.015 4.14 0.015 Nene known. 3.97Spleen 0.015 4.14 0.015 3.82Muscle 0.015 4.12 0.014 WARNINGS 3.32Testes 0.013 3.52 0.012 In studying patientswith knownor suspectedcoronary artery disease,care should be taken 3.05Liver 0.013 3.41 0.011 toensurecontinuouscardiacmonftonngandtheavailabilityofemergencycardiactreatment. 4.15Thymus 0.012 3.22 0.015 PRECAUTIONS 2.54Brain 0.012 3.11 0.009 2.15Lungs 0.010 2.72 0.008 General 2.08Skin 0.008 2.27 0.008 Tominisnizeradiationdose to the bladder.the patientshouldbe encouragedto void whenthe 1.91Breasts 0.008 2.22 0.007 examination is completed and as often thereafter as possible.Adequate hydration should be 0.008 2.22 0.007 1.83 encouragedto permftfrequent voiding. DosecalculationswereperformedusingtheStandardMIRDmethod(MIRDPamphletNo.1(rev).Soctatyof The contents of the Myoviewvial are Intendedonly for use In the preparationof technetium NucfearMedicine,1976).EffeCtivetheeequivalents(EDE)werecalculatedInaccordancewithtCRP53(Ann. Tc99m tetrofosminInjectionand are NOTto be administereddirectlyto the patient. ICRP 18 (1-4)1988) andgavevaluesof8.61 x iO@mSV/MBqand 1.12a 10' mSV/MBqafterexerciseandrest, As with all Injectabledrug products,allergICreactionsand anaphylaxismay occur. Sometimes Tc99m labeled myocardial imaging agents may produce planar and SPECT Imageswith dIfferentlma@nginformation. Manufacturedby: TechnetiumTc99m tetrofosmin Injection,like other radioactivedrugs, must be handled with NycomedAmershamplc care and appropriatesafetymeasuresshouldbe usedto minimizeradiationexposureto clinicai AmershamUnitedKingdom personnel.Care should also be taken to minimize radiatiOnexposureto the patient conwistent wIth proper patient management. PatentNo.5,045,302(r) Radiopharmaceuticaisshouldbe used by or underthe controlof physicianswho are qualified by specific training and experience In the safe use and handling of radionuclides,and whose DIstrIbuted by: experience and training have been approved by the appropriate governmental agency Medi-Physics,Inc., authorizedto licensethe use of radionuclides. ArlingtonHeIghts.IL 60004 Drug Interactions:Drug Interactionswere not noted and were not studiedin dinical studiesin 1-800-633-4123(TollFree) which Myoviewwas administeredto patients receivingconcomitantmedication.Drugs such as beta blockers,calcium blockersand nitrates may Influencemyocardialfunction and blood flow. The effectsof such drugs on Imagingresuftsare not known. Circle Reader Service No. 135 Carclnogenesls,Mutagenesls,ImpaIrmentof FertIlIty Studies havenot been COnduCtedto evaluatecarcinogenicpotentialor effectson fertility. Tetrofosminsutphosalicytatewas not mutagenicin vitro in the Ames test, mouse lymphoma, or human lymphocytetests. nor was ft claStOgeniCin vivoin the mouse micronucleustest. PregnancyCategoryC Animal reproductionstudies have not been conductedwith Myoview.It is not knownwhether Myoview can cause fetal harm when administered to a pregnant woman or can affect reproductive capacity.Therefore, Myoview should not be administered to a pregnant woman RevisedDecember1998 unlessthe potential benefltjustlfles the potentialrisk to the fetus. Myoview is a trademark of Nycomed Amersham plc. NursIngMothere TechnetiumTc99m pertechnetatecan be excretedin human milk.Therefore,formula should be substituted for breast milk until the technetium has cleared from the body of the nursing woman. BS-43-1011A VAmersham HEALTHCARE @ z: —@

.@

@ _@&@._.d @ ‘. @ .- . -V-....-@ - . @ .

,‘,.-@ @.;‘. “p

/ I 6

@ h@' p.',.

BI0DEx @uj .@__•__@_@

BiodexMcdicalSysiems,Inc. ‘BrookhavenTechnologyCenter. 20 RamsayRoad‘Box 702 . Shirley. New Yrk ‘11967-07)2 .9000 ‘Fax631-924-9620 @@: .@ :@i @NUCLEARMEDICINE6 CARDIOLOGY—------.--@-@SYSTEMS

introducingtheall newPowerPCSCINTRONV computerforGEandSIEMENSGammaCameras Re-manufacturedNuclearMedicineGammaCameraandnew SPECTComputer System for the budget-conscious facility. WithchoiceofSiemensor GeneralElectricSPECTgantry,(37, 75 or 61 PMT's).ThenewPowerPCScintronVcomputerisa sophisticated,high-speed .‘l AcquisitionI Processingworkstation,allin onepackage. @ .______-@-@-@ ‘ ;.

CAMERA COMPUTER

- .

VI Just like NEW VI Completely NEW @ I

I New Crystal with VI Full Simultaneity —---— 3 years warranty! VI Gated Cardiac V/ Laser Imager SPECT Interface r(@u@1j_LI•- ‘/ Fast Processing ‘I Optional Whole Body I Optional Tele.. Radiology

Complete systems Detector and Gantry are fully re-manufactured. MiE America Inc. is ISO 9002 certified. Crystal replacement on Siemens BODYSCAN, DIACAM as well as ORBITER and GE 400 ACT! Service Contracts are available. Leasing starts as low as $1400.00 I month. The Reimbursement is the same. The Image Quality is the same. Why Pay More?

@— @_ -4 @ I%@.i-@1 SCINTRON V u@arade for your existing SIEMENS eliminates your DOT, ICON , Scintiview or Micro Delta.

SCINTRON V up2rade for your existing General Electric eliminates your STAR computer or STARCAM components.

MiE's Upgrades eliminate most of OEM electronics, and brings your system up to a state-of-the-art, digitally controlled camera with high speed processing computer, at very reasonable cost. LET US BUILD ONE FOR YOU! SCINTRONV with @mefISSP!CTGantry MiE America - 695 Lunt Ave. Elk Grove Village, IL 60007 - Phone: 1.847.981.6100.-.Fax: 1.847.981.3232 MiE Germany - Moorweg 9-11 D-23845 Seth - Phone: 011.49.4194.99770 - Fax: 011.49.4194.997755

CircleReaderServiceNo. 125 @ N to

theAbilfl of

a a 0

4 a, 0 0 V

C 0 a, C

0 5. a t 0 0 0 a.

YourNuclearMedicine

@ H@-- -@ --- ‘@--@-@-@- - and Equipment? Then look no further than the SNM Proficiency Testing Program

Using phantoms—three-dimensionalsimulatorsof various malities. The Quantitative Cardiac Phantom will test a par anatomical regions—you can identify whether your cameras ticipant's ability to acquire and process SPECT rest/stress are providing quality output and measure the proficiency of myocardial perfusion. your nuclear medicine staff. By sending your results to SNM, you'll also be able to compare your individual results with Each study costs $625 for SNM members or $695 those of other participants. VOICE credits available. for nonmembers, plus $35 for shipping and handling. The Lung Perfusion Study is designed to detect the loca Save $70 when you order both. For information or tion, extent and significance of simulated perfusion abnor to order, call (703) 708-9000 x1321. , SOCIETYOFNUCLEARMEDICINE 0

CONTROL THE PROCEDURE

1.I@'@ a

,‘l@ )fr

S

.u /

@ F@'

ci

/, ‘.

:‘-;:::

I Precisely.

During SPECTimaging with pharmacologic stress, you don't want any surprisesfrom your vasodilator.

Adenoscan—clockworkprecision.

Its rapid action and ultra-short half-life (<10 sec.) mean that you're in control of your procedure. In general, Adenoscan'seffects are well tolerated and spontaneouslyresolveafter infusion.

It'spredictable.It'sreliable.

Adenoscangivesyou pharmacologicstresspreciselythe way you want it.

Control with confidence ADENOSCAN® adenosine injection 1-800-888-7704www.adenoscan.com

Intravenous Adenoscan®(adenosine injection) is indicated as an adjunct to thallium-201 myocardial perfusion scintigraphy in patients unable to exercise adequately. Side effects that were seen most often included flushing (44%), chest discomfort (40%), and dyspnea (28%). Side effects are seldom serious, usually resolve quickly when infusion is terminated, and generally do not interfere with test results. Despite the short half-life of adenosine, 10.6% of the side effects occurred not with the infusion of Adenoscan but several hours after the infusion terminated. Also, 8.4% of the side effects that began coincident with the infusion persisted for up to 24 hours after the infusion was complete. In many cases, it is not possible to know whether these late adverse events are the result of Adenoscan infusion. Please see the briefsummary ofprescribing information on the following page.

02000 Fujisawa Healthcare, Inc. A5763 7/00 BRIEPSUMMARY ADENOSCAN@ adenosineinjection [email protected]

@ Adenoáiw@dogenca@deà @cek@body. @ —. It‘Ss@ub@iiwaterandpmctica@yi@so@em@cohoLSo@htyi@creasesbywanmngand

RIRICAflONSANNRIAG@ @ @;@N@@cane i@dicatedana4nct totha1hum@2O1m@vc@perfüaionacihy ii p@ientaunth@toexaiciead@iat&y.

co@R@ knousMenocaiabotIdn@be@eed@idvidu@with: @ 1. Se@n@orthi&de@eeAVbIock(eaepti@patienIawitha. . @fici@ —@tha@ aft6d@

4. Kn@nP@@eraenestMtytoadenoama WARNINGS Fat@card@carrest,sustainedventndulartac@ard@(reqiling resuacitadon),andnonfat@myoc&dial @farctionhavebeenrepcxted @ @iiciderdwithAdenoec@@i@ueót beav@th@a

(0.8%)bestb1o@Al epiaodeOIAVblod ha@bean @npIomatic@tr@ien@and @dn@rec@[email protected]@icitMenoecancancaiaewta I, p@iMaw@@Pi@Pgad,AVbioduwaiiusnodedv@undion(eaceptmDabents@aftincliaIina@tiñci@pacem@er).Menccw @oiidbe @@::d@@Lw!pahflt who devdope pera@(entor e)@nptcmatic11i9h@@AV b@[email protected]@iuspwae has been rareêyobeeived @th

@ kueaaesm @* @@okprea@nhavebeenobeerved( greet 140mmHgsy*Ac monecaae)concomitantwithAdenoecan @@fueion;most @@creaee$reeotvedspontaneouslywithi@sever@minutes,butin somecaae@hypettension@stedfor sever@hovr@ Menoeca@I ame@toIy @iaMt@[email protected]@dbodydw'w@.@ andi*a@enoue @airi@r@onmmanhas @ @eas(dyepnas) anurgeto breathedeep'yw@iMenoec@mean,eepiabycon@à iá@eiranelerdaidcn@yoeIy requie

@ftonandhatani@e aTheas@have notbeenobeenedmnonaaIaub@ect@Adenoecanhasbeenade*@emdtoaftniIednuniw@

@moNt @ @b*venousMenoeca@h been @venwfth c@scdevoeidee@andc*Aum thannelb@odiei.)without @perentadverseiiteraction@butftaeffect@nesswfththeseagsntshasnotbeensvsfemahcalvevaft@sted @ has@MenOe@iehOIidbeUeedW@canftOn @ enchas@tcandinee(e.g. celfeioeandthen@hi@l:@1hae@ andethcacyof Menoecw@ii thepreeenoeoftheseagentshasnotbeensvstematscailvevaluated. @ a thepias@i*atde,tndanolehasnatbeene@ele,oeticaI@ev@ed W@enevevpoee@ciugsthatm@dat*at aqnerd thealledsof @ I,— al@oiid@ @ Ci LSI5@j Ste Csisa Ct@ areasloans @o@j y.*iogericpotent@ofMenoecatMenoã@ewasnegativebgenotosácp@enftaI @ noe ft side mc eyc a r@i e, @M*iatemdidiape,iIoneal@onoeadayIorbasdayeat5O,100,and 150 @ .- - 30 , amy basiel caJSeddec,easedepem@O@enealSand1@c,eeSednUmbemof @ apem@i no@ xk eomaldwi@ega Pt*[email protected]@yC

The@wd&tecftvaneasofMenoecanm@ntsleesthan18yearsofa@ehavenotbeeneetabfishe@

metee@uiare@iooewrn@aniiodenoeofatleast1%werereportedwithi*avanousAdenoecwaniong1421patIentSeIiOIedmCOnIICISdand tmcor*oIecEU@thicalv@ De@theal@oittatI4eofedenoei@@10.MoftheideefhcteocctxrednatwdhtheiiftaionofMenoscanbid asvaralhaursall&thealontemdM@&4%oftheade@idsthatbeaancoincideMwiththeidueionpeiietedteriete24hou,aalter thei@ieionwasc@ate. him@ case@fts nc*poee@htelu@owwhetherlheeeteteadvemeevents @athereetitofMenoecanidueior@ Rushing 44% Geatrointeetinaldiacomlod 13% SeCOndde@eeAVbIOdI 3% cheati@ea@ndod 4@ L@edeee&de@eas 12% Pare@eala 2% D@ipnascwiigete&e@ha@ 28% UpperedVemftycISCOmIOII 4% l@x*enelun 2% Hesdecd@e iRIb &aeqnvaddefAeeeion 3% Nsvauenees 2% Throatoethw@wdeccn*d 15% FEat-cM@eeAVblud 3% Mh$fflas 1% Mvaras@encasofanyasved@yreportedi@hasthan1%ofpahentsi@ckide: BoyasaWhols@decctnfort @astremiIydiecomtoit;we@neee. @ (systo@cbfoodpreeeure>200mmHQJ.

@ SCOSOmas@tenguadecOmbt

Thehalf-tieofadenoeiries leesthen10secondsandaideeftectsofMenoecai(whentheyoocur)ueudyresolvequiddywhenthei@lueiona @ decoiatnued,@hou@@del@sedpersistenteffectshavebeenobeeivedM@h@1oeata@e@auth callemeandtheoohalI@@econçatiftve adenoelnerec@dor@dagon@andtheo@4@ehasbeenusedtoeffedivelytemi@ peraiiei*ide alte@hiconioledU@dtecalteal@ theoptee@125mgal@m@nousqec@on)wasneededtoalortMenoecwade&tectsmlessthan2%O(pa1Ien@ DOSAGEANDADMINISTRAUOIt F@avenouei@lueluna4 Adenoecanahoi1dbe@venasaco,alnuousperj*ieraii,fravenoueidusion. @ co@en@o@eesor@tea i@omc@n@a There@eddoesofthaltum@201ahouldbei@ectedatthemk@dthe Adenoecani@fualon@ie@afterthefntthreeminutesofAdenoecan). @ @fldium-201 lifualoneeL The@echonehoiddbeasdosetethevanoueaccessaspoee@tefupreeentwiiadeetteOamasealthedOeeofMenOecan(thecOntentaofthe @ Nhibm@

Rocwdy F%@Hedthcw@ Deeifietd,1L60015 4700lIReeiae&.hpd2000

CircleReaderService No. 50 September 8, 2000 Hampton Inn & Suites Warwick, RI Need to get up-to-speed FAST on APC codes and CPT codes for nuclear medicine? @.;:‘4 Get all you need to understand the major procedural aspects of nuclear medicine services, including proper code selection, claim submission and documentation in this one-day workshop. Discover how to use the current CPT and ICD-9-CM manuals. Find out how to cost a procedure. Get tips for working with your hospital billing department to assure nuclear medicine procedures are correctly covered by third party payers. Evaluate your coding and billing practices in light ofthe new APC codes and reimbursement for radiopharmaceuticals. And so much more.

For additional information, call (703) 708-9000 x1255.

Society of Nucr― @ i.@fAustralasian;@RADIOLOGY.@2 ‘. Australasi an RADIOLOGY

‘@e0.4 ,?@, Thisinternationallyrespectedjournal,ofmorethan40yearsstanding,

@. ‘ publishespeer-reviewedoriginalpapersandcasereportsIndiagnostic

I radiologyandradiationoncology. TheJournalattractssubmissionsfromaroundtheworld,areflectionofits e$@t@ ‘@. internationalappeal,reputation,andcontinuedencouragementoforiginaldata, ideasandinterpretation.AustralasianRadiologyistheofficialJournalofThe RoyalAustralianandNewZealandCollegeofRadiologists. AbstractingandIndexing Editor ADONIS,AIDSInformation,APAIS,CambridgeScientificAbstracts,Cancer TherapyoftheUpperGastrointestinalTract,CanceLIlEmbase/Excerpta MichaelR Sage Medica,IndexMedicus,IntemationalNursingIndex,InternationalNuclear FlindersMedicalCentre,Adelaide InformationSystems,MEDLINE,OncoDisc,UnCover@UniversityMicrofilms, UrologicalOncologyUpdate ISSN0004-8461 Volume44 ForaFREEsamplecopyandAuthorInstructionsvisit: 4 issuesperyear www.blackwellOscleNce.com/ara

SubscriptionRates2000(Australianresidentspleaseadd10%GST) @ PrintOnly I@ Australia/NZAus$269.00 RestofWorldUS$259.00 @ OnlineOnly E@Australia/NZAus$242.10 RestofWorldUS$233.10 @ Both Austraiia/NZAus$295.90 t@ RestofWorldUS$284.90

- @.]I.]1:ia.i:I@i - I@ PleaseentermysubscriptiontoAustralasianRadiology2000atthesubscriptionratetickedabove L@Ienclosepaymentof cheque(Australiaonly)I bankdraft1postalorderpayabletoBlackwellScienceAsia (Australianresidentspleaseadd10%GST) @ I wishtopayby Visa E@AmericanExpress DinersE@Mastercard JCB I@ Bankcard PIeasedebitmycardNo.@@JI@[IIHlI1ILjIjf

Amount Expirydate I ...... Signature I@ PleasesendmeafreesampleissueofAustralasianRadiology

Mama Address @ Postcode..... Telephone Fax Email b Returnthisformto:BlackwellScienceAsia Blackwell P.O.Box378,CarltonSouth,Victoria3053,AustralIa ScIence Fax:+613 93415001 EmaIl:[email protected] Asia @ I

IsYourNuclearMedicineDeixwtment BeingLeftOutOfYourPACSPlan?

Nuclar Workstation _____ DICOM

Nuclar Workstation DICOM printer

Nuclonr WOrkstatiOn DICOMstorage

@ D haveoldernuclearmedicinesystemsthat Ifyournuclearmedicines@temsaren'ttalkingtoyour aren'tDICOMcompliant? PACSnetwork,thenyoushouldbetalkingtoMedlmage. DELlAmanager®can interfaceto all nuclear medicine systems,oldandne@thensendthedataoutviaDICOMlink@― toyourPACSnetworkfordisplay,printor archive. A Medlmije°° themedicalimagingspecialists

DELTMnana@rb a re@oi trademarkandDIcOhThnkb atrzlemarkdM@I1mage,Inc 734-665-5400 www.medimage.com734-665-4115fax Circle Reader Service No. 122 Call for * Papers The Journal of Nuclear Medicine (JNM) @ and nonmembers are to submit papers for publi in the JNM. Papersreporting from clinical and research ThI1@of all specialties are Brief communications

— preliminary research results in an abridged paper are especially desired. JNM is indexed in Index Medicus and on MEDLINE. Information for authors is available at: www.sflm.org/pdf/infoauth_999.pc.jf Please forward submissions to: Martin R Sandier, MD The Journal of Nuclear Medicine fr@ Society of Nuclear MedIcine I 850 Samuel Morse Drive Reston, VA 20190-5316 ,tSOCIETYOFNUCLEARMEDICINE Nuclear Medicine Week gives you the oppor tunity to educate potential patients, referring physicians and your community about the history, value and safety of nuclear medicine. We have posters, balloons, buttons and much more to help you decorate your office, lunch room and department to promote your spe cialty. Hand out this year's themes' pens, pencils and pads of paper to referring physi cians, nurses and administrators in your hos pital and/or institutions. If you are a nuclear medicine industry partner use these items to thank your valued customers.

Keep the celebration alive all year long! Promoting nuclear medicine does not need to be limited to Nuclear Medicine Week. Take advantage of every opportunity throughout the year to increase the under standing and utilization of nuclear medicine.

n n

\•@Zj1Uj@:12I aL@d@[@3[@:

@ I' 1

0@E\0UCL'@aiv1

Balloons ?SocietyofNuclearMedicine NUCLEARMEDICINEWEEK October 17, 2000 ORDERINGINFORMATION (NoteAllordersmustbeaccompaniedwiththisorderform.)

Pre-payment via check, VISA or Mastercard required for all orders. F.@&913-362-7401 Call Toll Free: 800-829-7062 Mall: MidPointNational Attn: Society of Nuclear Medicine P.O. Box 411037, Kansas City, MO 64141-1037 ITEM QUANTITY PRICE TOTAL

Pens (Purple) packs $8.00/pack (6 pens) Pens (Red) packs $8.00/pack (6 pens)

Pencils ______packs $6.00/pack (12 pencils)

Balloons (Purple) .50@/per balloon

Balloons (Red) .50@t/per balloon Pads of Paper packs $8.00/pack (3 pads)

Buttons $1.50/perbutton

Posters $5.00/poster

Shipping: (allow 2-4 weeks for delivery) For domestic shipping: $10 or less add $4.00 $lO.0l-$20.Ol add $6.00 $20.Ol-$30.Ol add $8.00 $30.00 or more add $12.00 For international shipping: $25 for any international order For Express delivery: $25 (allow 3-5 days for domestic delivery and 2-4 weeks for international delivery)

TOTAL:

INFORMATION:1@PAYMENT

MastercardCreditCheck (payable to the Society of Nuclear Medicine)Credit CardVISAt@ No.:______Exp.Date:______CardCard Name:CardHolder's Signature:SHIPPINGHolder's INFORMATION:EXPRESSORDERSCANNOTBESHIPPEDTO A RO. BOX.

Name: Phone:______

Institu@―@―LLI@JII. Address:. Address:. City:_ State: Zip: — Ti

.JUNE 23-27. 2001

II

@ ‘FU R () N 0 , 0 N @FA 14 1 0 . C A N A I)

Breakthroughs. Interactions. Insights. Visions.

The world's premier nuclear medicine meeting and exhibits.

Annual Meeting: June 23-27, 2001 @*fr;@ Exhibits: June 24-27, 2001

p

SOCIl@l'V 01―NtUI@I';@R \lII)IUINI @:;@

@ ; y_@: .@,. @ [email protected]@h@rso1dIlillalti

Applications are invited for the 2001 Paul C. Aebersold Award for outstanding achievement in basic science applied to Nuclear Medicine. This award commemorates the

.4,@ contributions of Dr. Paul Clarence Aebersold to the applications of nuclear physics to Nuclear Medicine and radiation biology, as well as his contributions to the Society ofNuclear Medicine (SNM). Dr. Aebersold contributed greatly to the emergence of Nuclear Medicine as a discipline by his energetic leadership in the provision of cyclotron-generated and reactor-produced radionuclides, and by his numerous publications and lectures. In giving this award, the Society thus symbolically signifies its appreciation ofthe warm and vital person who became the Society's first Honorary Member.

Nominations should be supported by the nominee's curriculum vitae and at least two letters supporting the nomination. These letters should briefly describe the contributions in basic science for which the nominee is proposed. The nominee does not need to be a SNM member.

Nominations deadline: December 3 1, 2000. Please submit nominations and supporting documents to William J. Maclntyre, Ph.D., do Society ofNuclear Medicine, 1850 Samuel Morse Drive, Reston, Virginia 20190-5316. ‘@ NuclearMedicine Radiologist department. Contact Sandi Grant, Chief Technolo PositionsWanted Multi-hospital, subspecialized, progressive private gist, CNMT, at (404) 321-61 11, ext. 6156. Physician, ABNM, ABIM, and CBNC certified practice radiology group in south Denver with new needed. NW USA. [email protected]. clinicalPETfacility.seeksBoard-certified,NucMed AcademIc Nuclear Radiologist fellowshiptrained radiologistwith additional skills in Thfts University School of Medicine and New Eng NUclearMedIcine body imaging. Prefer recent fellowship orjunior fac land Medical Center, a full-service hospital with a Ochsner Clinic in New Orleans seeks a Board Certi ulty.Partnershiptrack. Send CV attention: MatthewJ radiology residency. seeks second ABR certified! fled Section Head for Nuclear Medicine tojoin our Fleishman MD, RIA, 3900 S. WadsworthBlvd.,#250, eligible nuclear radiologist (full-time position). sixteen physician Department of Radiology. This see Lakewood, CO 80235. Fax: (303) 788-6546. With six gamma cameras (three multihead SPECT), tion does approximately550-600exams per month. this interesting practice opportunity includes Thecandidatemustalsobequalifiedto teachin our NUclear Medicine ThIUIOIOgISt nuclear cardiology, pediatrics, coincidence imaging, freestandingresidencyprogram.Candidatesshould Memorial Medical Center, a flagship of Memorial and radionuclide therapy. Duties include some gen have completed an accredited training program. Health System in Springfield, IL, is currently seek eralradiology.WillconsiderABNM-certified!eligi Fellowship training in PET is desirable. Ochsner ing a full-time technologist. Must be licensed in Illi ble nuclear medicine physician (part-time). Position is a physician owned and directed multi-specialty nois and ARRT or NMTCB. We perform the most available September 1,2000. Please send CV to: group practice. which includes more than 400 physi basic exams to advance applications including anti Daniel H. O'Leary, MD, Chairman, Department of cians in 27 locations across Southeast Louisiana. body scans, coincidence detection and cardiac imag Radiology, New England Medical Center-Box 380, We offer an excellent salary, fringe benefit package ing. If you enjoy variety, focus on quality, and want to 750 Washington Street, Boston, MA 02111. Phone: and paid vacation. Interested physicians should send work with a group ofteam oriented technologists who (617) 636-8050. Fax: (617) 636-0041. E-mail: Cvandcontact:EdwardI.Bluth,M.D.,Chairman are patient focused then this is the team for YOU! [email protected]. Department of Radiology, Ochsner Clinic, 1514 We have a comprehensive benefits package and salary Jefferson Highway, New Orleans, LA 70121. is commensurate with experience. Inquiries contact Nuc Med Thclis Information: (504) 842-3470 or e-mail: Dawn Kinner, Human Resource Generalist, (217) The Fideis Group Consultants currently hasjobs for [email protected]. 757-7729, 701 N. 1st St., Springfield, IL 62781. Nuc Med Techs in 28 States! If you want to make a Website: www.memorialmedical.com. E-mail: change, we will contact hospitals for you! (877) 329- NUcIe*rMedlcine Physician [email protected]. Fax: (217)788-5539. 1119.www.fidelisweb.com The UniversityofCalifomia, Davis,Departmentof Radiology has a full-time faculty position available for Nudear Medicine lèchnologist Chief, Section of Nuclear Medicine a board certified radiologist with fellowship training The VeteransAffairs Medical Center—Atlanta The Department of Diagnostic Radiology, Yale Uni and boardcertiflcation in NuclearMedicine. Appoint VAMC.seeks an energetic Nuclear Medicine Tech versity School of Medicine seeks applicants at the ment will be at theAssistant, AssociateorFull Profes nologist to join a talented team of professionals AssociateProfessor level or higher for the position of sorlevel. Candidates must be eligible forlicensure in focused on providing quality care to the nation's Chief, Section ofNuclear Medicine,and depending California, have an academic and clinical background veterans. The VAMC has a state-of-the-art depart on qualifications, DirectorofPE'Fand!or Radiochem in Nuclear Medicine,and be able to provide coverage ment that performs both clinical and research proce istzy Laboratories. The qualified applicantmust have in cross sectional imaging.This position will be “open dures using five gamma cameras (4 SPECT systems demonstratedexcellence in research, teaching. and until filled,―but applications will not be accepted after and a coincidence system). Qualified candidates program administration. Please send curriculum vitae Januaiy 31, 2001. Please send a curriculum vitae to: must be graduates ofAMA-approved schools of to: Dr. Broce L McClennan,Chair. Departmentof James A. Brunberg, MD, Chair, Department of Radi Nuclear Medicine and be CNMT and/or ARRT Diagnostic Radiology, Yale University School of ology. UniversityofCalifomia, Davis,4860 Y Street. Nuclear Medicine certified. They must have SPECT Medicine, P.O. Box 208042, New Haven, CF 06520- ACC Building, Suite 3100, Sacramento,CA 95817. experience and strong computer skills. Preference 8024. YaleUniversity is an equal opportunity!affirma The UniversityofCalifomia, Davis, is an affirmative will be given to candidates with at least three years tive action employer.Applicationsfor women and action/equal opportunity employer. of experience in a progressive nuclear medicine minority group members are encouraged.

Nuclear Medicine The Dept. of Radiology at Wayne State University Clinical Fellow in PET Imaging and the Detroit Medical Center is currently recruiting an ABR-certified nudear radiologist with additional ABNMcertificationorABRspecialcompetencein The Division of Nuclear Medicine of the Mount nuclear radiology. The candidate must also be able Sinai Medical Center is offering a fellowship to cross over in general and cross-sectional radiology. in PET imaging, featuring oncological and The position is available July 1, 2000. The dept. offers an extremely competitive compensation pack cardiac applications, starting July 1, 2001. age as well as an opportunity to actively participate Candidates must have completed a nuclear med in its teaching and research programs. icine residency, be board eligible in nuclear Interested candidates should send a medicine and must be trained in cardiac stress current CV and introductory letter to: testing and monitoring. Interested candidates should send inquiries and CVs to: Lawrence P. Davis, MD, F.A.C.R, Interim Chair Dept. of Radiology DRH 3L8 Josef Machac, MD 4201 St. Antoine Director of Nuclear Medicine Detroit, MI 48201 Mount Sinai Medical Center Phone: (313) 745-3430 Box 1141 Fax: (313) 577-8600 E-mail: [email protected] One Gustave L. Levy Place New York, NY 10029 Equal opportunity employer

Classified 41A -J Providence Health System Mak@ig a Difference in Oregrn

@ ‘--@- -.@- . .@— . . - -.

Providence Health System, the second largest private employer in Portland, Oregon, is recognized as a quality leaderin bothhealthcareandtheworkenvironment.Providence,rankedasoneofthe 100bestcompaniesto work for in Oregon, has been named as one of the top 100 Integrated Healthcare Systemsin the nation and among the nations BestHospitals. We currently have the followingopportunity: ***We offer Sign-on Bonuses and Relocation*** Nuclear Med Tech We are currently seeking a Nuclear Med Tech for our department, which consists of 5 technologists, including a supervisor, two secretaries and two physicians board certified in nuclear medicine. Equipment includes three SiemensOrbiters, one whole body scanner and an ADACMCDscanner for PETimaging.Allradionuclide procedures, including imaging monoclonal antibody and PETare performed. Must be CNMTor ARRTcertified. Rotatingcall required. For the Nuclear Med Tech position, please direct inquiries to: Providence Employment Center, Ref#NMT/JOURNC, 4805 NE Glisan St., Portland, OR 97213; fax: (503) 216-4652; phone: (503) 215-5770; or e-mail to: [email protected] Applications are required and may be obtained by visiting our website at: [email protected]

We offer the most advanced technology, competitive salaries, and a generous flexible benefits program. Benefits include: Medical, Dental, Long Term Disability, Life and AD & D, Paid Time Off up to 26 days a year, Extended Illness Time, Tuition Assistance, Fitness Center, Free Bus Passes and/or Employee Parking. just to name a few! While the Providence mission will inspire excellence in your career, Portland's easy access to ski resorts, beaches and wilderness trails will invigorate your life outside of work. \@kare an Affirmative Action Employer in a Culturally Diverse Workplace. I I l@ 100BEST It' p A caring dIff.r.nc. you can f.I @ _, . — • ____u_ @.. ._FD? _ ‘

FACULTY POSITION

DiagnosticImagingand/orTargetedRadiotherapy Purdue University seeks an outstanding scientist to fill a faculty position at any rank in the Department of Medicinal Chemistry and Molecular Pharmacology. Applicants should have research interests and experience in innovative molecular approaches to diagnostic imaging and/or targeted radiotherapy. The successful candidate will be expected to establish and/or maintain a strong, extramurally funded, research program at the interface of medicine and chemistry or biology. A commitment to excellence in teaching at the under graduate and graduate levels will also be required. The Department has a vigorous and growing research environment with first-rate instrumentation, and maintains an active and successful program in Nuclear Pharmacy. Opportunities exist to participate in numerous interdepartmental programs, such as the Purdue Cancer Center, the Purdue Neuroscience program, and cross-disciplinary biomedical imaging initiatives. Candidates must hold a PhD; junior-level candidates should have at least two years of postdoctoral experi ence. Minority and women scientists are especially encouraged to apply. Applicants should submit a curriculum vitae, a detailed description of research plans, and three letters of reference to: Imaging/Radiotherapy Faculty Search Committee Department of Medicinal Chemistry and Molecular Pharmacology Purdue University, School of Pharmacy ‘333RobertHeine Pharmacy Building West Lafayette, Indiana 479071333 Reviewof thecandidateswill beginOctober, 2000andcontinueuntil thepositionisfilled. PurdueUniversity is an EqualOpportunity/Affirmative Action Employer

42A THEJOURNALOFNUCLEARMEDICINE•Ml. 41 •No. 9 •September2000 NUCLEARMEDICINEPHYSICIAN

BODYIMAGER Doctors Medical Center is a 392-bed facifity that The Department of Radiology of the RoswellPark offers a hospital-based nuclear medicine position. Cancer Institute, Buffalo, New York, seeks a Board The Imaging Department offers three certified Certified,fellowship-trained,BodyImager.Familiarity Nuclear Medicine Technologists. The hospital is with all bodyimagingmodalities-MR, Clultrasound andfluoroscope-is required,aswellasahigh comfort located in the Central Valley of California. Seeking levelwith awide variety of CF and altrasound-guided an ABNM Board Certified (or eligible) candidate percutaneousinterventional procedures. RoswellPark for July 2001. PET experience preferred. 5000 is a SUNY Buffalo affiliate, with academic appointments for its staff, protected academic studies per year. Expansion of the department is time, and a highly competitive salary/benefits slated for this next year. Modesto is a tertiary referral package. The department includes state-of-the-art center for a six-county region and offers a strong imaging technology in a new $240 million hospital/ economy and excellent educational, recreational institute compleL and CUltUralamenities. We are offering a competitive Please call Zachery D. salary and benefits. For more information about Grossman, MD, Chair, Department of Radiology The Doctors Medical Center, visit our website at Roswell ParkCancerlnstitute, or www.dmc-modesto.com. DonaldLKlippenstein,MD,Vice Chair,TheRoswell ParkCancer If you would like to find out more about this Insititute,(716)845-8015 orE opportunity, please contact Wanda Holder mail: [email protected] or man in Business Development at Doctors [email protected] Medical Center, Modesto, California at (209) Elm I Cadlos Struts RPCI and the University at 576-3790. Fax (209) 576-3680. [email protected] Yolt 142k Buffaloare M/F/D/V Affirmative E-mail: [email protected]. ‘.soo.RoSw(LL Action Employers. EQE. M/F/D/V

Indiana University Department of Radiology Nuclear Medicine Positions Nuclear Medicine Faculty. Tenureor clinical trackrankdependenton qualifications.Candidatesmust be board-certified in nuclear medicine and have fellowship training. Salary and academic rank will be commensurate with experience and qualifications. Minimum requirements include M.D. and eligibility for licensure in Indiana. Submit CV to Dr. Mervyn Cohen, Chairman, Dept of Radiology, Indiana University Hospital, #0663, 550 N University Blvd. Indianapolis, IN 46202-5253; fax (3 17)274- 1849; mecohen@iupuLedu.

Clinical PET Director. Tenureor clinical trackrankdependenton qualifications.Candidatesmust be board certified in nuclear medicine and have fellowship training. Salary and academic rank will be commensurate with experience and qualifications. Minimum requirements include M.D. and eligibility for licensure in Indiana. Submit Cv to Dr.GaryHutchins,Director,PETFacility,Dept ofRadiology, 541 Clinical Drive, CL 157, Indianapolis,IN 46202-5 111; fax (3 17)274-8 124; [email protected].

Nuclear Medicine Fellowship. - Fellowship position for a board-certifiedor board-eligibleradiologiststarting July 1, 2001. This one-year position will be full-time in our ACGME-accredited nuclear medicine program. The clinical portion includes in-depth experience in full range ofdiagnostic and therapeutic procedures. A wide range ofongoing research projects under the mentorship ofwell-trained experienced physicians are available to the fellow. There are four hospitals in the program (including a free-standing Children's Hospital and a PET imaging center), all within walking distance of each other. Contact Aslam Siddiqui, MD, Dept of Radiology, Riley Hospital (I 053L), Indianapolis, IN 46202-5200; FAX (317)274-2920; [email protected].

A m*@ OV ‘U. Soixtcw MEL)ICAL . MBIUNE GROUP For more information, visit http://www.indyrad.iupui.edu Depttnme@uoIRada,&ie, —cur. IndianaUniversityis an EqualOpportunity/AffirmativeActionEmployerM/FID.

Classified 43A NuclearMedicineTechnologist NuclearMedicineRadiologist Salisbury,Marvianil Charlotte Radiology, a large (44 member) Why vacation at the beach when you can live there? private, subspeciaky based radiology practice Peninsula Cardiology is a progressive, 13-physician is seeking a partnership track, ABR certified practice located in Salisbury, Maryland on the beau tiful Eastern Shore, only 30 minutes from Ocean and fellowship trained radiologist to serve as City and within easy driving distance of several major Director of Nuclear Medicine. This is a full metropolitan areas. We offer a competitive wage and service nuclear department which includes PET benefit package and relocation assistance. We have an scan and Cyclotron. Radiologic skills in cross immediate opening for a Nuclear Medicine Technol sectional imaging desirable. The practice ogist in the expanding Nuclear Department of our Cardiology Practice. No weekends or on-call work. covers multiple hospitals in a large metropol The successful applicant must be certified, or be itan area including a tertiary care hospital with registry eligible for, an approved program in nuclear a Level I trauma program. Total number of medicine. One-year experience in nuclear medicine beds exceeds 1300. There are also eleven out preferred, but not required. patient offices. Send resume to: Please submit your resume with a cover letter to: A. Van Moore, Jr., M.D. Peninsula Cardiology Associates, PA do DlannMcGuirt Human Resources Department Dept. N.M. 400 Eastern Shore Drive CharlotteRadiology,P.A. Salisbury, MD 21801 P.O. Box 36937 Charlotte,NC 28236-6937 EOE

ill fcarewi4@a@@

,. futukofadvan@c

San Antonio Community Hospital has been taking very good care of our community since 1907. when it was just a small stone building. That small hospital has evolved into a 33o-bed acute care facility serving the western portion of the Southern California Inland Empire. Yet. even with advanced medical services and the finest technology, we haven't lost that hometown community feel. Many of our employees were born here and have relatives who have worked with us. Nuclear Med Technologist As a Nuclear Medicine Technologist, you will perform nuclear medicine studies, determine appropriate isotope required, review patient's condition. develop film and assist with scheduling of exams. Position requires an individual who has completed an accredited program in nuclear medicine. who holds and maintains (via required continuing education credits) current certifications from the ARRT and/or NMTCB. CRT (Nuclear) and possesses a Healthcare Provider CPR card.

We are committed to advancement from within and strong management support. in addition to competitive salaries and benefits packages. For immediate consideration, send resume to: Human Resources Dept. NMT/JNM. 999 San Bernardino Road. Upland, CA 91786. E-mail: [email protected] Jobline: (909) 94.90719. Background checks and drug screening are part of our pre-screening practice. EOE. 4

San AntonioCommunity Hospital Visit us on the Web at www.sach.org Qualityhealthcarefromgenerationtogeneration.

44A THEJOURNALOFNUCLEARMEDICINE•\bl. 41 •No. 9 . September 2000 NUCLEAR MEDICINE ATIENTION! TECHNOLOGIST ACADEMICRADIOLOGISTS! Long hours, case overload, threatened salary cuts, POSITIONS AVAILABLE staff implosion, mythical “academictime―,and deteriorating equipment —all for less than half of what your colleagues are earning in private practice? $6,000 If these circumstances apply to you, or soon SIGN-ON BONUS will, consider Body Imaging at The Roswell Park Cancer Institute, a state-of-the-art facility in $60,000 - $75,000... Buffalo, New York. No, we don't offer private practice salaries, but we do

. . .guaranteed first year compensation plus offer a most congenial working environment, a rca sonablecaseload,ahighlycompetitive salary/benefits excellent benefits for qualified applicants. package (on the academic scale), truly protected aca Paid vacation, sick & holidays. 401-K, demic time, pioneering research, superior equipment, anewhospital, andapleasant,low-pressuredepartment. Medical/Dental, full-time income guarantee. Ifyou are approaching burn out Day shift (with very little call and weekends), in the frenetic environment of weekend only shift, & night shift available. your current situation, call Zachary D. Grossman, MD, Just 30 minutes from sunny California beach Chair, Department of Radiol es, PMI is the largest mobile nuclear medicine ogy,The Roswdll Park Cancer Institute, (716) 845-8015 or provider in the state. Very friendly and profes E-mail [email protected] We sional work environment. Call 562-777-1010, IT,..? are the alternative to the aca demic pressure cooker and the or mail resume to PMI, Attn: BR, 12130 Mora @. El. S Csrtto. Strusts private pressure cooker. @o.@wY@tiau Drive, STE 1, Santa Fe Springs, CA 90670, RPcI and the UniversityofBuffalo are 1'$OO'ROSWELL @ Fax: 562-777-1050. M/F/D/VAffirmativeActionEmployers t,@. r

NUCLEAR MEDICINE 7 1@ 7! Call for TECHNOLOGIST Providence Yakima Medical Center in Central Washington is seeking a Nuc Med Tech to support a full range of services in an acute care hospital Papers setting. Requires current registry from a Nuclear Medicine Technology Certification Board, Washington State Certified RadiologicTechnologist or The Journal of Washington StateRegisteredX-RayTechnicianandWashington StateHealth Care Assistant. At least one year experience preferred. Nuclear Medicine We offer a competitive salaty comprehensive benefits package and reloca. tion assistance. For consideration please fax your resume to (509) 577. (JNM) 461 1; e.mail: [email protected]; or mail to: Providence Central and nonmembe@are invitedto Washington Service Area, Human Resources, 110 South 9th Avenue, submit papers for publication in the JNM. Yakima, Washington 98902. EOE. Papers reporting results from clinical and @ research investigations of all specialties are @@1@*h[ProvidenceHealthSystem welcome.Brief communicationsdetailingpreliminaryresearch results in an abridged paper are especially desired. JNM is indexed in IndexMedicusand on MEDLINE. INTERESTEDIN PLACINGANAD? Information for authorsis availableat: www.snm.org/pdf/infoauth_999.pdf Toplacea classifiedadvertisementinthe JNMor JNMTpleasee-mailor faxthe copyto the Please forward submissions to: AdvertisingDepartmentwhowill furnish an estimate. Martin R Sandier, MD Hospitalandcompanylogosareacceptedelectronically The Journal of Nuclear Medicine foranadditionalcharge.Lineadsare$30perline. Society of Nuclear Medicine 1850 Samuel Morse Drive Reston, VA 20190-5316 For display rates contactStacey Silver at: Phone:(703)326-1183 Fax:(703)708-9018 t SOCIETYOFNUCLEARMEDICINEE-mail: [email protected]

Classified 45A @ .@.

@J)1)@t) .-. ‘,1)10 \P1'@ 1 CMEUnllmltedlsproudtobe — #22 (4lapes,$44) ATThE

.- — I the offidal recordIng and marketing INTERFACE OF MOLECULAR BiOLOGY

@ —.-—-@* - company for the Society of Nuclear @ o\I@\l1:N() I Dtl( .@ — Medicine's47thAnnualMeeting. —#23(4Tapes.$44)PEDIATRIC @ held June 3-7, 2000, In St. LouIs. NUCLEAR MEDICINE: ADVANCES FOR TIE @ L )URSIS_ NEWMILLENNIUM @ . , MissourI. - voo@(1Vk@o) Audio and video cassette copies of — #24 (3lapes,$33) IOIFDGPET/ SPF.CT- CUNICAL ADVANCES IN PET/ —#1(1AudIo)cAMEaA-RASaD sessIons lIsted below are avaIlable vIa METHODS101 Ql ESUMAUON- SPECT Andrew i: Taylor,Jr..MD; Gary F.Gates, MD TELEPHONE, FAX, MAIL or ONUNE @ . ORDER. All orders will be shipped r FEMIC.\1 —voo-2t1Video) within 10 business days. @ —#2(1AudIo)NEWCONCEPTSIN L @)tIRS1S liE 11ERAPYO@LYMPHOMA—James To order Immediately. have your —#25WHOLEBODYPETFDGIN Cox. MD; Donald A. Pbdoloff. MD credit card ready and call toil-free I -800-776-MM from [email protected]. to CANCER PATIENTh - READ WITH lilT (Anas Ycunes. MD was not recorded) 5:00 p.m. (PSi). Monday - FrIday, or vIsit the SNM Online Tape Store EXPERTS(R.EdwardColeman,MD wasnot —VOO-3(1Video) via www.CMEunIImIted.orajsnm. Formall or FAX —#3(2Audlos)MANAGEMENTOF orders. piease mark your selections. compiete —#26RADIOSIOLOGICALUFECTS ILPIIGNTHY@OWDISOIDERS—JamesC. the coupon on the opposite page. indude OF IONIZINGRADIATION(RUE) @ 5@ssI@n,MD; I. McDougall.MD, PnD Mi payment, and send this entire order form coNnNUINGwUCAnON@RADIOwOL OGY I - VOO-4(1Video) to CMEUnlimited. —#4(1AudIo)UCHP4IQIJL,CLINiCAL Foryour convenience, we accept —#27SCINTIMAMMOGRAPHY— RotaANDLCONOMICSOFIMA@NG MasterCard, VISA, and AmerIcan Express READWiTHThE EXPERTS ChILDRENWDH URINARYTIACT as weil as checks.Thankyou. INff@1ON - Robert HOWmSO-GIIesMD; —#28V/QANDHELICALCTINTHE DIAGNOSiS OF PULMONARY EMBOLISM MkhaelJ. GeIfan@MD —#29RADIOB1OLOGICALEFFECTS —Voo's(lVideo) OF IONIZINGRADIATION(RUE) ..,....#5(lAudIo) SNMTAPESPECIALS CONTINUINGEDUCATION: MYOCAIDIALFUNCTiONAND RADIOWOLOGYU PEIFUSION:6 ThEIE ADDITIONAL Product Descit@on Price NA@OSTK ANDPIOGNOSTIC VALUE? —#30MAKINGMYOCARDIAL — Michael k Freeman. MD; Dank! S. PEUUSION SPECT @UPIETAflONS Berman. MD (audio tape only; not on Individual Video (VHS) Tapes (non-member) S49.95 CLINICALLYRELEVANT- READWITHThE video); Salvador Borges-Neto. MD VIdeo PAl. I SECAM Tapes S 59.95 79.95Individual$Aityindividual Video PAL I SECAM Tapes (flee-member) — VOO@6 (I Video) —#31ACUTEABDOMINALPAIN: —#6(1AudIo)TI@RELEVANCEAND S216.00Full8 VIdeo (VHS) Tapes ($27.00/each) (member) DIA@'4OSllC DILEMMAS S368.00IndMdualSet of 16 Video (VHS) Tapes with Free Albums (member) ASSESSMENTOF MYOCARDIALVIAIILITY — #32 CALCULATION OF ABSORBED —Jamshld Maddahl. MD; Rob Beanlands. @ MD (Steven Bergmann.MD. PhD was 1.00Any AudIo Tapes SI DOSE: FROM INtERNAL DOSE TO RELEASING PATENTS FROM THE not recorded) S84.00Any8 AudIo Tapes ($10.50/each) HOSPITAL (Richard B. Sparks, PhD was not S160.00Any16 AudIo Tapes with Free Album ($10.00/each) —Voo-7(1VIdeo) 32 AUdIO Tapes with Free Albums ($9.50/each) S 304.00 —#7(1AudIo)UINGNODULES Full Set of 151 AUdIO Tapes with Free Albums $1,050.00 —#34INTERPRETINGVENTRICULAR KeithS. Naunheim. MD;JayBlum,MD; FUNCTION STHDIES - READ WITh ThE Vail. Lo@. MD EXPERTS - VOO'8(1Video) —#35FEDERALAGENCIESAND —#8(1AudIo)QUANTIFICATiONOF — VOO-11(4Videos) NUCLEAR MEDICINE MYOCARDIAI.PELFIISION—HOW TO —#II(4Audlos)CLINiCALPOSITRON APPLYA CLINICALPIACTICE— IMAGING EXPERT FORUM - —#36PARATHYROIDLOCALiZATION Gibert A. Hurwltz MD; PlotrSlomka; PaulC.Hanson,CNM1@FSNM7S;Steve — # I 5 (3 Tapes. $33) FEDERAL GRANT Torres.RFH;SteveKohlmyer,MS; LonnieM. FUNDING FOR BIOMEDICAL @AGNG —#37SPECTBRAINIMAGING ErnestV C.arcia@PhD(audiotapeon'y; PRACTICAJ1ICIINICAI. ASPECTS noton video);JohnJ.Mahmarlan.MD Mixon; PatDevlln, CNMT DonaldM. Torre. CNM1@Andre Vanuffel(CJaIreT Terry,DOt — # 16 (4 Tapes, $44) EVALUATING PET @ ts4#@@. ‘- . . . .:. . RTandJOnFreywere not reco.rded) SCANNERSFORCLINICALUSE — #38 MONOCLONAL ANTIBODIES IN ONCOLOGY- READWITHThE — #17 (4lapes,$44) 1HEROLEOF @ —VOO-12t1Video) NUCLEAR CARDIOLOGY IN 2000 @ _#12(lAudIo) —#39MYOCARDIALPERFUSiON IMAGiNG AND TECHNIQUES —Douglas — #18 (2lapes,$22) 101 FDGPET/ IMAGING IN ACUTE CORONARY —VOO-9(2Videos) Murray,MD; PattiL. Corrlgan.Langford. SPECT - FUNCTIONAL IMAGING AND — #9 (2 Audlos) RADIATION SAFETY CNMT CLINICAL ADVANCES — James E. Carey, Jr.. MS. DABR@ Robert T — #40 (2 Tapes, $22) Ai@gee Jr.. MS (Note: The Impact on the Day — #19 (3lapes,$33) IDAREGULA COST-EFFECTIVENESSOF FDGPETIN TORY FRAMEWORK FOR PET to-DayI@actIceofNucIearMedlcine wasnot ONCOLOGY recorded) —#20(4Tapes,$44)CUTTINGEDGE OF CLINICAL NUCLEAR MEDICINE —#41SPECTBRAINIMAGING @ — VOO-1O(1 Video) —#13 PRACTICA:ROUTINECLINICAL —#10(1AudIo)UPDAThON A Edward Coleman — #21 (3Tapes,$33) T1IEUSE A@UCATIOND LEGiSLATIVE AND LIGULATOIY MATTERS OF ALPHA-EMITTING 5OTOPES @ IN NUCLEAR MEDIONE — William R. — #14 (ZTapes, $22) IN PEE-CLINICAL AND CLINICAL TRiALS —#42COST-EffECTIVEDIAGNOSIS @ Uffe!man, £sq.;Valerie Cronin, CNMT ANNUAL MUTING IllGJUJGIITS - (RonaldD.Finn,ThD;MarcoChInOI,PhD;and OFCORONARYARTERYDISEASE @ KathyHaney.MS;L!saAnnTrembath.BA. Hefty N. Wagner,MD Mkhael k Zalutsky,PhD @verenot recorded) (RobertC Hende!,MD wasnot recorded) CNMT @

rii@'€@

#56 EMERGING ROLE OF RADIO #71 TiE BUSiNESS OF MEDICINL (4 Tapes, $44) BREASTCANCER OVERVIEWPHARMACEUTICALSURROGATES IN TiE AN ETHICAL CHALLENGE#85 ASSESSMENTOFTRERAPWE1C( #86 EDUCATORSFORUM: @ MOTIVATION TO @ () N TI N III\ ( i I I) tI( U I( ) N TELEMLOICINE A LEGAL POINT LEARN @ C()tJRSI S@IARMACEUflCALSOFVIEW #72(3Tapes,$33)EMERGING #58 ABSORBED DOSE EST1MATES #87 15 CARDIACSESSIONU @ iLR@ CONFERENCE(M@itM BO)'d. @ #43 (2 Tapes. $22) IWDATES IN (@pajr@j@@.p@jjc@ TO @ IMAGINGANDTHERAPYOFTHYROID p@j@p@p@(@%[email protected]@,C. Stabin, G'@@ FSNM7Swas not recorded) #88 EDUCATORSFORUM: @ CARCINOMAS— EVALUATiON— TECHNOLOGIST— PhD @vesnotrecorded)— —#73(3Tapes.$33) NIAPPUCATIOPISTIE#44 SPELT BRAIN IMAGING HOW TO IDENTIFY EXAM:REVIEWSESSIONI#89 TS CARDIAC SESSiON @ PRACTPCA:ADVANCEDCLINICALes@ @j@r@ijj - u.@ @miCERTIHCATION IMAGING— EXPERTS— #74(4Tapes,$44)CLINICAL#90 (2 Tapes. $22) LUNG MEDICINEIN TiE NEW @ #45 TUGIMAGINGONPET SOMATOSTATIN-BASED TapeS.$33)ThEBUSiNESS CAMERAS - READ WITH TIlE EXPERTS FNN@ (JamshldMaddahl, MD was j@p@ AND ThERAPY (ErkP V..rennlng, not recorded)— SWE OF NUCLEAR MEDICINE (M@Cle ft MD, PhDwasnot recorded)NUCLEAR recorded)CARDIAC— #46 ATTENUATiON CORRECTiON INi@ B@Yt@CNMJ FSNM1S was not @ STUDIES(Robert C Hende!, MD TapeS,$33)TESTYOUR IN DIAGNOSiSANDTREATMENT wasnotrecorded) óPii.OLOGY/CARDIOLOGY (Jamshid TECHNICAL AND CLINICAL SKILLS READ OFCOLORECTALCANCERIN ThENEW Maddahi.MD wasnot recorded)— WITH ThE EXPERTS@2 and——#47 [email protected]@ss MILLENNIUM (Munlr V C.f,esanl, MD #62(2Tapes.$22)BRAIN (3 Tapes, $33) 101 FOGPET/ Dehdashtl. MD were not recorded) #48 CAMERA QC AND ACW CONTINUING EDUCATION COURSE @pcc@- rurtaio@ i@w@G @o TANCE TESTING ADVICE FOR THE NOVICE— @ BRINGING— READ WITH liE EXPERTS#76 CLINICAL ADVANCESFarrokh — (2 Tapes, $22) #49(2Tapes,$22) YOURCLINIC #63RADIONUCLIDEThERAPY: #78(3Tapes,$33)MANAGEMENT %@DA1LIN GFJIRAL NUCLEARMEDICIPE FROMCIJNICALTRIALTO CLINICAL @ TWSON RUNNINGAN EFFECTIVENUCLEAR — (2 Tapes, $22) PROSTATE -Tiff ALASBIMNPERSPECTIVE- PRACTICE AN INTERACTIVESESSION MEDICINEDEPARTMENT —#64BASiCPRINCIPLESOFCOST @ — #50 SUCCESSFULLY ESTAILISHING — (2TapeS.$22)PEDIATRIC EFFECTiVENESSOVEROUICOMIS STUDIES —#79(2Tapes,$22)NUCLEAR A HYBRIDPETIMAGINGCENTERIN ThE MEDICINEENHANCINGPRARMACEUfl COMMUNETYSETTING @ .-@i ACQUISITIONANDPROCESS lIE ROLE OF TIE TECIINOLO -* INGOFMYOCARDIALPERFUSIONSTUDIES — #51 LYMPHOSCINUGRAPHY: BASiC INTIIEVEAR2000 .:.. OBJEC1'lVES CONCEfl@RADIO@IARMACEUDCALS #80 EDUCATORSFORUMTO @ AND1T.CHNICALACcREDITAUON—CONSIURRATIONS— (2Tapes.$22) TiE SENTINEL— AND TAPES,—#52 PACS- HOWTOCHOOSEONELYMPHNODEIN SURGICALONCOLOGY#81 EDUCATOR'SFORUM:JRCNMTFOR VIDEO #68TiEDECiSIONMAKING THE #53 MYOCARDIAI. PERFUSION PROCES& UNDERSTANDINGUE SNM ONUNE TAPESTORE SPECT: HOW TO DIFFERENTIATE BEAUTY LITERATUREWORKSHOP — #82 PEPUDE ADVANCES IN TiE @ viaEXPERTSFROMARTEACT- READWITHTIE— @r@j@tr@OFLUNGVISIT #69 GRANTFUNDING

— #54 MILTIMODAUTY APPROACH #70 BASICPRINCIPLESAND TO STAGE LYMPHOMA TECHNICAL CONS1DIRATIOP6 OF MULTI AMERICANS WEDS DISARU.FUES ACT lEAD GAMMA COINCIDENCE IMAGINGa@ °R CALL TOLL4REE — #55 PEDIATRICS - READ WITH TIE EXPERTS— —#84(2Tapes,$22)1SCARDIAC (800) 776-5454 SESSIONIaa@i

@ PLEASE PPJNTcLEARLYORATTAOI YOUR 81.1518855 CARD BUSINESS @ORESS@RESDENTIALADDRESS @dD Prk. individualVideoTapes S_____ Individual Video @ss. S 29.95 NAME Non-m.snb.rs . S 49.95 kidMdual MIJSECAM ... S 59.95 _____FullSet(s)ofVideosS______@IJSECAM(non-members). S 79.95 AnySVId.o(VHS)...... S 216.00 ____ individuaiAudio Tapes S______members ($27.Oweactt) - member UKttl Full S.t of 16 VIdsos (VHS) . S 368.00 with FreeAlbums- member ____ FullSet(s)of Audios S______

CITYSTATEZIPTELEPHONEE-MAIL hdvi@aaiAudlo@ S 11.00 At:y 8 AudIo @ss S 84.00 SUBTOTAL $ ______($10.50/each) ORFAX Any16Audio@ss..... S 160.00 Local California Sales Thx .. S_____ with Free Album ($10.00/each) lfsN@ to California @ msnwcsvi iwusi [email protected] uisucss r uu#sn@wv,eeL) •Ass. 3@MLC@rim@. Any32Audio@ S 304.00 0 cexorrCARD(V@&MasterCar@AmericanExpress)0 aiscic(paysbeetoOAtUniksfted) with Free Albums ($9.50/each) Shipping & Handling S____ Full 5t of 151 Audio @p.s $1.050.00 Add$1.75perAudio;Mm. U.SO.Max.$12. with Free Albums Add $3.00 per Video; Max. $15. \ _J__J_J___J_J___J__J CombinedMaximum$18.00 ,,,‘ACCOUNTNUMBER Out of USk Add 20% ofSubtotal or $3.50 Mm. @ (Cassettes purchased ibr ToCanada:Add 15%ofSubtotalor $3.50Mm. i_i /__J_J ______professionalor charitablepurposes TOTALPRICE P. DATE(Rsquir.d@ SIGNATURE(R.qulr.d) SNM 0006OJNM t1@i may be a tax deductible expense)

74-923 Hoviey Lane East, Suite 250 toll-free (800) 776-5454 Palm Desert, CA 92260 C@IE phon. (760) 773-4498 fax (760) 773-9671 web www.CMEunilmited.org UNLIMITED•e-maIl infooCMEuniimited.org

SNM @ ‘@@L

BERLEX

@ .

@-.. @ 7 1 S.@ :T@@ @.

.,. (

@—‘artneringfor the Advancement of Nuclear Medicine

As a specialist in nuclear medicine, you understand the value that partnering can bring to your patients. Combining your knowledge and experience with the right equipment, products, and supplies, you create a synergy of elements that offers the best chance for successful diagnosis and treatment. Synergy for Better Patient Care Berlex Imaging understands your drive to enhance diagnostic and therapeutic performance to deliver your patients the highest level of care. Sharing these same goals, Berlex Imaging has recently created an alliance to raise the level of excellence in nuclear medicine imaging and therapy. Each partner brings a variety of strengths to this alliance: •Berlex Imaging introduced the first MRI intravenous contrast agent and is the undisputed market leader. Central to the philosophy at Berlex Imaging is personal involvement in the fields it serves, as evidenced by its outstanding record of continuing education and customer service programs.

C Diatide has pioneered innovative peptide engineering and technetium radiolabeling chemistry, producing “smartdrug―technology to “find-fight-follow―TMdisease. •CIS-usisaleadingsupplieroftraditionalradiopharmaceuticalsforthediagnosisandtreatment of tumor pathologies and diseases of major organ systems. Furthering Our Commitment to Nuclear Medicine This new alliance, under the Berlex Imaging name, is committed to continued advancements in nuclear medicine diagnostics and therapies. Berlex Imaging is dedicated to bringing you “everythingyou need to see:' from radiology to nuclear medicine, and beyond. IMAGING ©2000,Berlex Laboratories, Inc.All rights reserved.Code#OONM1 Everytbingyou need to see

CircleReaderServiceNo.9 Leadership in nuclear cardiology.....

It's our Forte@

A complete offering in cardiology

\

Superior camera technology •Vantage ExSPECT helps to increase diagnostic confidence with non-uniform attenuation correction, scatter correction, resolution recovery.

•CardioTrac roving ZOO@ eliminates truncation artifacts by keeping the heart in the center field of view during acquisition.

•Remhrandt long bore collimators minimize dead space.

complemented by the industry's best software tools:

AutoSPECT Plus' CardiaQ AutoQUANT'@ InstIll―

. Aut@SPFCT PIus@ Automated SPECT, •Comprehensive Cardiac Quantitation •Autiirnateii Cardiac Quantitation for •Corrects all types of motion

@ Vantagc@& MCD@ Processing S Access to All Data Files in One Application MD Interpretation •Intelligentmotion detectionalgorithm S One Button Processing . Software Suite Provides Rapid MD Review •Fully automated for all cardiac . User Configurable for MD Preferences S High Accuracy (93.7@ Overall) . Published Validation SPECT imaging

ADAC ADAC Laboratories AiMC AtJSiRAiiA (@i2-99O4i()() ADAC BRAZ. St-i l-K22-@t@6 ADAC CANAi)A 905-Si t-i3@O A1MC CHiNA (uangzhmi) Ss.2(J-$i-ssiS ADAC i)ENMARK 4S-95-it3soi ‘ @tn.l FOR MORE INFORMATION CALL: A:)A(: EUROPE Nc.hcrIand.@ii-5)-24245()() ADAC FRANCF ii-i-bOslOi4i Ai)A(; Gi@RMANY 49-21 i-4i5.2() AI)A( iTALY i9-2-224i 015 ADACJAPAN ii I-5291-2i9() 800-538-8531 A1M( PACiFIC (Si,gaporc) @c-St;-O#@SS Ai)AC UNiTED KiNGi)OM 44-i844-280i1 www.adaclabs.com

Circle Reader Service No. 1